Target intelligence / Profile preview

Plasmodium haematin detoxification system (HDS)

Target
HDS
Molecular classification
Metabolic pathway, Biocrystallization process, Other
01

Overview

The Plasmodium haematin detoxification system is a vital metabolic pathway employed by Plasmodium species to neutralize the toxic byproducts of hemoglobin digestion (Sullivan, 2002, PMID: 12456505). During the parasite's intraerythrocytic stage, it consumes host hemoglobin, releasing free heme (ferriprotoporphyrin IX), which is highly toxic due to its ability to generate reactive oxygen species and disrupt lipid membranes (Egan, 2008, DOI: 10.1016/j.drudis.2008.01.004). To survive, the parasite converts this free heme into an insoluble, non-toxic crystalline polymer called hemozoin within its acidic food vacuole (Hempelmann, 2007, PMID: 17368387). This process is often facilitated by the Heme Detoxification Protein (HDP) and specific lipid environments (Jani et al., 2008, PMID: 18451171). This system serves as the pharmacological target for quinoline-based antimalarials, such as chloroquine and quinine, which bind to heme or the growing crystal face to inhibit further detoxification (Coronado et al., 2014, PMID: 24954177). The resulting accumulation of free heme leads to parasite death, making this system one of the most successful targets in antimalarial chemotherapy.

Other names
Hemozoin formation pathwayHeme biocrystallizationFerriprotoporphyrin IX detoxificationMalaria pigment formation
02

Mechanism of action

Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free ferriprotoporphyrin IX (Sullivan, 2002, PMID: 12456505).

03

Biological functions

Heme detoxificationMetabolic waste sequestrationIron homeostasisOther
04

Disease associations

Infection
05

Safety considerations

Drug resistance (e.g., PfCRT mutations)Retinal toxicityCardiotoxicity (QT prolongation)Neurotoxicity
06

Interacting drugs

Chloroquine

7 more in the full profile.

07

Biomarkers

Hemozoin levelsParasitemiaPfCRT mutationsPfMDR1 mutations

Beyond the preview

Go deeper on Plasmodium haematin detoxification system (HDS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium haematin detoxification system (HDS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call